January 2026

Biotechnology OLMA Uncategorized

Olema Oncology announces departure of chief operating and financial officer

Jan 30, 2026

Biotechnology GLMD Uncategorized

Galmed Pharmaceuticals receives Nasdaq bid price deficiency notice

Jan 30, 2026

galmed-pharmaceuticals-announces-receipt-of-nasdaq-minimum-bid-price-notification

PR Newswire

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Jan 30, 2026

TEL AVIV, Israel, Jan. 30, 2026 /PRNewswire/ — Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or...

nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635(c)(4)

PR Newswire

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 30, 2026

SAN FRANCISCO, Jan. 30, 2026 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) today announced that, on...

gut-microbes-shape-cancer-growth-and-immunity-through-asparagine-metabolism

Cancer Genetics News Uncategorized

Gut Microbes Shape Cancer Growth and Immunity Through Asparagine Metabolism

Jan 30, 2026

Evidence has been rising over the past few years that the gut microbiome can significantly...

AMGN Biotechnology KYKOF Uncategorized

Amgen ends collaboration agreement with Kyowa Kirin for eczema asset

Jan 30, 2026

Biotechnology INCY MGNX Uncategorized

Incyte wins EU backing for MacroGenics-partnered cancer drug in GIT indication

Jan 30, 2026

kos-biotechnology-partners-announces-inaugural-investment,-leads-epikast’s-financing-round

PR Newswire

Kos Biotechnology Partners Announces Inaugural Investment, Leads Epikast’s Financing Round

Jan 30, 2026

Alex Tzoukas joins Epikast’s Board of Directors Epikast co-founded by biotechnology luminary Dr. Stelios Papadopoulos NEW...

Biotechnology PLX Uncategorized

Protalix says EU panel recommended a new dosing regimen for Fabry disease therapy

Jan 30, 2026

Biotechnology IMCR MRNA Uncategorized

Moderna announces departure of medical chief

Jan 30, 2026

« Previous Page — Next Page »